Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New colloidal gold test strip demonstrates great potential for early detection of heart attack

NYU Polytechnic School of Engineering professors have been collaborating with researchers from Peking University on a new test strip that is demonstrating great potential for the early detection of certain heart attacks.

16 Jan 2015

Universal vaccine against flu may be on the horizon, say researchers

The fact that this year's flu shot is not a good match against this year's influenza strain is well known, and has happened before.

14 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

Study finds difference between results from IHC and quantitative molecular techniques

The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.

12 Jan 2015

Pathologists use ProExC antibody cocktail to determine tumor recurrence

Partnering with head and neck surgeons, pathologists at Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center developed a new use for an old test to determine if a patient's cancer is recurring, or if the biopsy shows benign inflammation of mucosal tissues. In Pathology - Research and Practice, lead author Candice C. Black, DO explained how her team confirmed the utility of ProExC, an existing antibody cocktail commonly used for pathology tests of the uterine cervix.

12 Jan 2015

EMA accepts Praluent (alirocumab) MAA for review

Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.

12 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013.

8 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals, Inc. today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.

31 Dec 2014

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Retroviruses are best known for causing contagious scourges such as AIDS, or more sporadically, cancer.

23 Dec 2014

Experimental Ebola vaccine safe and immunogenic in African population

Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus [1] are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year.

23 Dec 2014

High speed, high resolution glycan mapping now achievable for mAb characterization

The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern. Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.

19 Dec 2014

Experimental drug warrants clinical study for treatment of Ebola infection

A case report, published in The Lancet today, describes the successful treatment of Ebola using a new drug under clinical development for vascular leakage (FX06, a fibrin-derived peptide).

19 Dec 2014

Endogenous retroviruses also play critical role in the body's immune defense against pathogens

Retroviruses are best known for causing contagious scourges such as AIDS, or more sporadically, cancer.

19 Dec 2014

Antibody News and Research

Further Reading

New colloidal gold test strip demonstrates great potential for early detection of heart attack

Universal vaccine against flu may be on the horizon, say researchers

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Study finds difference between results from IHC and quantitative molecular techniques

Pathologists use ProExC antibody cocktail to determine tumor recurrence

EMA accepts Praluent (alirocumab) MAA for review

Two new ODYSSEY trials meet primary efficacy endpoints

Proteomics market expected to experience continual growth

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

EnGeneIC closes oversubscribed Series B financing

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Patent recognizes peptide that reduces tissue damage

Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Experimental Ebola vaccine safe and immunogenic in African population

High speed, high resolution glycan mapping now achievable for mAb characterization

Experimental drug warrants clinical study for treatment of Ebola infection

Endogenous retroviruses also play critical role in the body's immune defense against pathogens

Antibodies eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News